The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France

Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France

“…The costs and impact on HRQOL of a disabling stroke were similar to those reported in other France-based analyses. 28,29 The disutility inputs were derived largely from the costeffectiveness study performed by Lanitis et al 24 ; this study based its data on an EQ-5D study conducted in a UK population. 30 Consideration should be given to how well these data truly generalize to a French population.…”

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review

“…From the perspective of scientific research, existing recommendations for analytic procedures in realworld-study-based CEAs remain insufficient [7,8,51]. Our analytic procedures for conducting a real-worldstudy-based CEA, which carefully consider study cohort comparability, the validity of effectiveness and cost parameter estimations, and the uncertainty of study data, results, and assumptions, provide a methodological framework for future real-world-study-based CEAs.…”

“…CEA results can support treatment prioritization, facilitate healthcare reimbursement policy formulation, and optimize healthcare resource allocation. The incorporation of real-world effectiveness and cost data into CEA complements the evidence derived from clinical trials and ensures that the results will be relevant for the real-life healthcare decision-making context [7,8]. However, most CEAs of GLP-1RA versus insulin therapy for T2D patients have been model-based (e.g., Markov modeling simulation) analyses that used data mainly derived from clinical trials that assessed short-term drug efficacy in terms of biomarker changes among highly selective and homogenous patient populations [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28].…”